Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
View in:
PubMed
subject areas
Administration, Oral
Animals
Antineoplastic Agents
Apoptosis
Biological Availability
Cell Cycle
Cell Line
Cell Line, Tumor
Cell Survival
Humans
Imidazoles
Immunoblotting
Insulin-Like Growth Factor I
Interleukin-6
Mice
Mice, Nude
Multiple Myeloma
Phosphatidylinositol 3-Kinases
Phosphorylation
Protein Kinase Inhibitors
Protein Kinases
Proto-Oncogene Proteins c-akt
Proto-Oncogene Proteins c-bcl-2
Quinolines
Signal Transduction
TOR Serine-Threonine Kinases
Xenograft Model Antitumor Assays
authors with profiles
Constantine S Mitsiades, Ph.D., M.D.
Kenneth Carl Anderson, M.D.
Paul Gerard Guy Richardson, M.B.,B.S.
Nikhil C Munshi, M.D., M.B.,B.S.